LinkedIn

 آمار

تعداد نشریات20
تعداد شماره‌ها1,210
تعداد مقالات11,009
تعداد مشاهده مقاله74,289,702
تعداد دریافت فایل اصل مقاله64,979,973
Nosrati, Marzieh, Izadidehkordi, Shadi, Nikfar, Shekoufeh, Heydari, Fatemeh Sadat. (1404). Cost-Effectiveness Analysis of Crizanlizumab in Sickle Cell Disease in Iran. سامانه مدیریت نشریات علمی, (), -. doi: 10.30476/ijms.2025.102567.3573
Marzieh Nosrati; Shadi Izadidehkordi; Shekoufeh Nikfar; Fatemeh Sadat Heydari. "Cost-Effectiveness Analysis of Crizanlizumab in Sickle Cell Disease in Iran". سامانه مدیریت نشریات علمی, , , 1404, -. doi: 10.30476/ijms.2025.102567.3573
Nosrati, Marzieh, Izadidehkordi, Shadi, Nikfar, Shekoufeh, Heydari, Fatemeh Sadat. (1404). 'Cost-Effectiveness Analysis of Crizanlizumab in Sickle Cell Disease in Iran', سامانه مدیریت نشریات علمی, (), pp. -. doi: 10.30476/ijms.2025.102567.3573
Nosrati, Marzieh, Izadidehkordi, Shadi, Nikfar, Shekoufeh, Heydari, Fatemeh Sadat. Cost-Effectiveness Analysis of Crizanlizumab in Sickle Cell Disease in Iran. سامانه مدیریت نشریات علمی, 1404; (): -. doi: 10.30476/ijms.2025.102567.3573

Cost-Effectiveness Analysis of Crizanlizumab in Sickle Cell Disease in Iran

Iranian Journal of Medical Sciences
مقالات آماده انتشار، اصلاح شده برای چاپ، انتشار آنلاین از تاریخ 08 مرداد 1404    اصل مقاله (506.46 K)
نوع مقاله: Original Article(s)
شناسه دیجیتال (DOI): 10.30476/ijms.2025.102567.3573
نویسندگان
Marzieh Nosrati1، 2؛ Shadi Izadidehkordi* 2، 3؛ Shekoufeh Nikfar1، 2؛ Fatemeh Sadat Heydari2
1Personalized Medicine Research Center, Endocrinology and Metabolism Research Institute, Tehran University of Medical Sciences, Tehran, Iran
2Department of Pharmacoeconomics and Pharmaceutical Administration, School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
3Department of Allied Health Sciences, University of Connecticut, United States
چکیده
Background: Sickle cell disease (SCD) prevalence is predicted to rise dramatically in the upcoming years. Although several medications have received Food and Drug Administration (FDA) approval in recent years, low- and middle-income countries (LMICs) still struggle to access these medications due to their remarkably high prices. Crizanlizumab, owing to its clinical and economic privileges, appears to be the most suitable option for addition to pharmacotherapy guidelines. However, no study has yet investigated its cost-effectiveness in Iran’s healthcare system. 
Methods: This cost-effectiveness evaluation was conducted in 2022 at the Pharmacoeconomic and Pharmaceutical Administration Department of the Faculty of Pharmacy at Tehran University of Medical Sciences, Tehran, Iran. A decision-tree model was designed, followed by a cost-utility analysis for crizanlizumab in two separate scenarios, targeting not only monotherapy with crizanlizumab in SCD compared with placebo, but also crizanlizumab’s concomitant use with hydroxyurea compared with hydroxyurea. The study reports the outcomes from Iran’s healthcare system perspective. Direct medical costs, quality-adjusted life years related to vaso-occlusive crisis, hospitalizations, and adverse effects were calculated. Incremental cost-effectiveness ratios were compared. SUSTAIN trial was the main clinical source for modeling crizanlizumab’s effectiveness in SCD. A sensitivity analysis was performed to measure the sensitivity of outcomes to changes in medication costs. Microsoft Excel 2020 was utilized for calculations and modeling. 
Results: Concomitant therapy with low-dose crizanlizumab added to hydroxyurea led to the lowest Incremental Cost Effectiveness Ratio (ICER) of 398,881 United States dollars (USD), exceeding Iran’s accepted cost-effectiveness threshold. Sensitivity analysis results demonstrate that even a 20% reduction in the price of crizanlizumab does not lead to its cost-effectiveness in Iran.
Conclusion: Crizanlizumab administration in sickle cell disease is not found cost-effective in Iran, neither as a monotherapy nor added to hydroxyurea.

تازه های تحقیق

Marzieh Nosrati (Google Scholar)

Shadi Izadidehkordi (Google Scholar)

کلیدواژه‌ها
Cost-effectiveness analysis؛ Crizanlizumab؛ Sickle cell disease؛ Sickle cell anemia؛ Adakveo
مراجع
  1. Kjellander C, Sennstrom MK, Stiller V, Agren A. [Sickle cell anemia causes varied symptoms and high morbidity. Serious prognosis in the most common genetic disease in the world]. Lakartidningen. 2015;112. PubMed PMID: 25734427.
  2. Collaborators GBDSCD. Global, regional, and national prevalence and mortality burden of sickle cell disease, 2000-2021: a systematic analysis from the Global Burden of Disease Study 2021. Lancet Haematol. 2023;10:e585-e99. doi: 10.1016/S2352-3026(23)00118-7. PubMed PMID: 37331373; PubMed Central PMCID: PMCPMC10390339.
  3. Dua M, Bello-Manga H, Carroll YM, Galadanci AA, Ibrahim UA, King AA, et al. Strategies to increase access to basic sickle cell disease care in low- and middle-income countries. Expert Rev Hematol. 2022;15:333-44. doi: 10.1080/17474086.2022.2063116. PubMed PMID: 35400264; PubMed Central PMCID: PMCPMC9442799.
  4. Piel FB, Rees DC, DeBaun MR, Nnodu O, Ranque B, Thompson AA, et al. Defining global strategies to improve outcomes in sickle cell disease: a Lancet Haematology Commission. Lancet Haematol. 2023;10:e633-e86. doi: 10.1016/S2352-3026(23)00096-0. PubMed PMID: 37451304; PubMed Central PMCID: PMCPMC11459696.
  5. Kato GJ, Piel FB, Reid CD, Gaston MH, Ohene-Frempong K, Krishnamurti L, et al. Sickle cell disease. Nat Rev Dis Primers. 2018;4:18010. doi: 10.1038/nrdp.2018.10. PubMed PMID: 29542687.
  6. Darbari DS, Sheehan VA, Ballas SK. The vaso-occlusive pain crisis in sickle cell disease: Definition, pathophysiology, and management. Eur J Haematol. 2020;105:237-46. doi: 10.1111/ejh.13430. PubMed PMID: 32301178.
  7. Jang T, Poplawska M, Cimpeanu E, Mo G, Dutta D, Lim SH. Vaso-occlusive crisis in sickle cell disease: a vicious cycle of secondary events. J Transl Med. 2021;19:397. doi: 10.1186/s12967-021-03074-z. PubMed PMID: 34544432; PubMed Central PMCID: PMCPMC8454100.
  8. Shah N, Bhor M, Xie L, Paulose J, Yuce H. Medical Resource Use and Costs of Treating Sickle Cell-related Vaso-occlusive Crisis Episodes: A Retrospective Claims Study. J Health Econ Outcomes Res. 2020;7:52-60. doi: 10.36469/jheor.2020.12852. PubMed PMID: 32685598; PubMed Central PMCID: PMCPMC7343342.
  9. Ataga KI. The challenge of clinical end points in sickle cell disease. Blood. 2023;142:2047-54. doi: 10.1182/blood.2023021220. PubMed PMID: 37890140; PubMed Central PMCID: PMCPMC10733825.
  10. Riley TR, Boss A, McClain D, Riley TT. Review of Medication Therapy for the Prevention of Sickle Cell Crisis. P T. 2018;43:417-37. PubMed PMID: 30013299; PubMed Central PMCID: PMCPMC6027858.
  11. Yenamandra A, Marjoncu D. Voxelotor: A Hemoglobin S Polymerization Inhibitor for the Treatment of Sickle Cell Disease. J Adv Pract Oncol. 2020;11:873-7. doi: 10.6004/jadpro.2020.11.8.7. PubMed PMID: 33489427; PubMed Central PMCID: PMCPMC7810265.
  12. Stevens DL, Hix M, Gildon BL. Crizanlizumab for the Prevention of Vaso-Occlusive Pain Crises in Sickle Cell Disease. J Pharm Technol. 2021;37:209-15. doi: 10.1177/87551225211008460. PubMed PMID: 34752581; PubMed Central PMCID: PMCPMC8255978.
  13. Ataga KI, Kutlar A, DeBonnett L, Lincy J, Kanter J. Crizanlizumab treatment is associated with clinically significant reductions in hospitalization in patients with sickle cell disease: results from the sustain study. Blood. 2019;134:2289. doi: 10.1182/blood-2019-125868.
  14. Smith WR, Ataga KI, Saraf SL, Adisa OA, Bailey M, Ramscar N, et al. The effect of crizanlizumab on the number of days requiring opioid use for management of pain associated with vaso-occlusive crises in patients with sickle cell disease: results from the SUSTAIN trial. Blood. 2020;136:32-3. doi: 10.1182/blood-2020-140428.
  15. Husereau D, Drummond M, Augustovski F, de Bekker-Grob E, Briggs AH, Carswell C, et al. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations. Value Health. 2022;25:3-9. doi: 10.1016/j.jval.2021.11.1351. PubMed PMID: 35031096.
  16. Gupta N, Verma R, Dhiman RK, Rajsekhar K, Prinja S. Cost-Effectiveness Analysis and Decision Modelling: A Tutorial for Clinicians. J Clin Exp Hepatol. 2020;10:177-84. doi: 10.1016/j.jceh.2019.11.001. PubMed PMID: 32189934; PubMed Central PMCID: PMCPMC7068010.
  17. Blair HA. Crizanlizumab: First Approval. Drugs. 2020;80:79-84. doi: 10.1007/s40265-019-01254-2. PubMed PMID: 31933169.
  18. Freitas SLF, Ivo ML, Figueiredo MS, Gerk MAS, Nunes CB, Monteiro FF. Quality of life in adults with sickle cell disease: an integrative review of the literature. Rev Bras Enferm. 2018;71:195-205. doi: 10.1590/0034-7167-2016-0409. PubMed PMID: 29324963.
  19. Jiao B, Basu A, Ramsey S, Roth J, Bender MA, Quach D, et al. Health State Utilities for Sickle Cell Disease: A Catalog Prepared From a Systematic Review. Value Health. 2022;25:276-87. doi: 10.1016/j.jval.2021.08.002. PubMed PMID: 35094801; PubMed Central PMCID: PMCPMC8804335.
  20. Ataga KI, Kutlar A, Kanter J, Liles D, Cancado R, Friedrisch J, et al. Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease. N Engl J Med. 2017;376:429-39. doi: 10.1056/NEJMoa1611770. PubMed PMID: 27959701; PubMed Central PMCID: PMCPMC5481200.
  21. Bertram MY, Edejer TTT. Introduction to the Special Issue on “The World Health Organization Choosing Interventions That Are Cost-Effective (WHO-CHOICE) Update”. Int J Health Policy Manag. 2021;10:670-2. doi: 10.34172/ijhpm.2021.105. PubMed PMID: 34634892; PubMed Central PMCID: PMCPMC9278374.
  22. Shah N, Bhor M, Xie L, Halloway R, Arcona S, Paulose J, et al. Evaluation of Vaso-occlusive Crises in United States Sickle Cell Disease Patients: A Retrospective Claims-based Study. J Health Econ Outcomes Res. 2019;6:106-17. doi: 10.36469/9667. PubMed PMID: 32685584; PubMed Central PMCID: PMCPMC7299444.
  23. Baldwin Z, Jiao B, Basu A, Roth J, Bender MA, Elsisi Z, et al. Medical and Non-medical Costs of Sickle Cell Disease and Treatments from a US Perspective: A Systematic Review and Landscape Analysis. Pharmacoecon Open. 2022;6:469-81. doi: 10.1007/s41669-022-00330-w. PubMed PMID: 35471578; PubMed Central PMCID: PMCPMC9283624
  24. Alashgar A, Holdford D, Pontinha V. PRO51 Cost Effectiveness of Crizanlizumab Compared to Hydroxyurea for Minimizing the Frequency of Vaso-Occlusive (VOC) PAIN Episodes in Patients with Sickle CELL Disease SCD from a Payer Perspective. Value in Health. 2020;23:S699. doi:10.1016/j.jval.2020.08.1787.
  25. Chen W, Howard K, Gorham G, O’Bryan CM, Coffey P, Balasubramanya B, et al. Design, effectiveness, and economic outcomes of contemporary chronic disease clinical decision support systems: a systematic review and meta-analysis. J Am Med Inform Assoc. 2022;29:1757-72. doi: 10.1093/jamia/ocac110. PubMed PMID: 35818299; PubMed Central PMCID: PMCPMC9471723.
  26. Dydyk AM, Jain NK, Gupta M. Opioid Use Disorder: Evaluation and Management. Treasure Island; StatPearls: 2025. PMID: 31985959.
  27. Ballas SK. Opioids and Sickle Cell Disease: From Opium to the Opioid Epidemic. J Clin Med. 2021;10. doi: 10.3390/jcm10030438. PubMed PMID: 33498726; PubMed Central PMCID: PMCPMC7865837.
  28. Arzoun H, Srinivasan M, Sahib I, Fondeur J, Escudero Mendez L, Hamouda RK, et al. Opioid Use in Patients With Sickle Cell Disease During a Vaso-Occlusive Crisis: A Systematic Review. Cureus. 2022;14:e21473. doi: 10.7759/cureus.21473. PubMed PMID: 35106256; PubMed Central PMCID: PMCPMC8786581.
  29. Zaidi AU, Glaros AK, Lee S, Wang T, Bhojwani R, Morris E, et al. A systematic literature review of frequency of vaso-occlusive crises in sickle cell disease. Orphanet J Rare Dis. 2021;16:460. doi: 10.1186/s13023-021-02096-6. PubMed PMID: 34727959; PubMed Central PMCID: PMCPMC8561926.
  30. Jiao B, Basu A, Roth J, Bender M, Rovira I, Clemons T, et al. The Use of Cost-Effectiveness Analysis in Sickle Cell Disease: A Critical Review of the Literature. Pharmacoeconomics. 2021;39:1225-41. doi: 10.1007/s40273-021-01072-z. PubMed PMID: 34368937; PubMed Central PMCID: PMCPMC10697726.
  31. Pires RP, Oliveira MC, Araujo LB, Oliveira JC, Alcantara TM. Impact of sickle cell disease on work activity. Rev Bras Med Trab. 2022;20:272-8. doi: 10.47626/1679-4435-2022-641. PubMed PMID: 36127913; PubMed Central PMCID: PMCPMC9458333.
  32. Adel AA, Abushanab D, Hamad A, Al-Badriyeh D, Yassin MA. L-glutamine and crizanlizumab for adults with sickle cell disease (SCD) in qatar: a cost effectiveness analysis. Blood. 2021;138:4945. doi: 10.1182/blood-2021-144636.
  33. Poppenborg F, Röth A, Yamamoto R, Reinhardt HC, Alashkar F. Crizanlizumab in adult patients with sickle cell disease: a retrospective German analysis. Frontiers in Hematology. 2024;3:1374181. doi: 10.3389/frhem.2024.1374181.
  34. Pontinha V, Almutairi M, Holdford D. POSB156 Cost-Utility Analysis of Crizanlizumab and Hydroxyurea in Preventing Vaso-Occlusive Events in Patients with Sickle-Cell Disease: A Lifetime Model from a Payer’s and Societal Perspectives. Value in Health. 2022;25:S91. doi: 10.1016/j.jval.2021.11.429.
آمار
تعداد مشاهده مقاله: 10
تعداد دریافت فایل اصل مقاله: 7


سامانه مدیریت نشریات علمی. قدرت گرفته از سیناوب